The reduction in price target by a reputable analyst like Morgan Stanley suggests a reassessment of Arrowhead Pharma's future financial performance or market position, potentially due to underlying challenges or slower growth expectations. This action can lead to a negative perception among investors, likely causing short-term price pressure.